The scientific community is working
against the clock to arrive
at therapeutic interventions to treat patients with COVID-19. Among
the strategies for drug discovery, virtual screening approaches have
the capacity to search potential hits within millions of chemical
structures in days, with the appropriate computing infrastructure.
In this article, we first analyzed the published research targeting
the inhibition of the main protease (Mpro), one of the most studied
targets of SARS-CoV-2, by docking-based methods. An alarming finding
was the lack of an adequate validation of the docking protocols (i.e.,
pose prediction and virtual screening accuracy) before applying them
in virtual screening campaigns. The performance of the docking protocols
was tested at some level in 57.7% of the 168 investigations analyzed.
However, we found only three examples of a complete retrospective
analysis of the scoring functions to quantify the virtual screening
accuracy of the methods. Moreover, only two publications reported
some experimental evaluation of the proposed hits until preparing
this manuscript. All of these findings led us to carry out a retrospective
performance validation of three different docking protocols, through
the analysis of their pose prediction and screening accuracy. Surprisingly,
we found that even though all tested docking protocols have a good
pose prediction, their screening accuracy is quite limited as they
fail to correctly rank a test set of compounds. These results highlight
the importance of conducting an adequate validation of the docking
protocols before carrying out virtual screening campaigns, and to
experimentally confirm the predictions made by the models before drawing
bold conclusions. Finally, successful structure-based drug discovery
investigations published during the redaction of this manuscript allow
us to propose the inclusion of target flexibility and consensus scoring
as alternatives to improve the accuracy of the methods.